Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mayuri Sharma

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Plos Medicine|June 17, 2025
Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in ThailandJing Shen, Elizaveta Kharitonova, Anna Tytula, et al.
Virology Journal|July 24, 2013
West Nile virus methyltransferase domain interacts with protein kinase GJulie A Keating, Dipankar Bhattacharya, Pei-Yin Lim, et al.
Journal of Virology|October 24, 2014
Human cytomegalovirus UL97 phosphorylates the viral nuclear egress complexMayuri Sharma, Brian J Bender, Jeremy P Kamil, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 8, 2015
Structure of a herpesvirus nuclear egress complex subunit reveals an interaction groove that is essential for viral replicationKendra E Leigh, Mayuri Sharma, My Sam Mansueto, et al.
Journal of Virology|February 22, 2013
Inactivation of retinoblastoma protein does not overcome the requirement for human cytomegalovirus UL97 in lamina disruption and nuclear egressNatalia I Reim, Jeremy P Kamil, Depeng Wang, et al.
The Journal of Infectious Diseases|December 3, 2022
Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement SystemEduardo J M Nascimento, Brooke Norwood, Eloi Kpamegan, et al.
Vaccine|February 21, 2026
Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trialSanja Mandaric, Heather Friberg, Raphael Gottardo, et al.
NPJ Vaccines|May 25, 2023
Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adultsInge LeFevre, Lulu Bravo, Nicolas Folschweiller, et al.
The Journal of Infectious Diseases|June 30, 2022
Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue VaccineChristina R DeMaso, Lovkesh Karwal, Melissa Zahralban-Steele, et al.
NPJ Vaccines|October 17, 2024
Long term T cell response and safety of a tetravalent dengue vaccine in healthy childrenSanja Mandaric, Heather Friberg, Xavier Saez-Llorens, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Plos Medicine|June 17, 2025
Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in ThailandJing Shen, Elizaveta Kharitonova, Anna Tytula, et al.
Virology Journal|July 24, 2013
West Nile virus methyltransferase domain interacts with protein kinase GJulie A Keating, Dipankar Bhattacharya, Pei-Yin Lim, et al.
Journal of Virology|October 24, 2014
Human cytomegalovirus UL97 phosphorylates the viral nuclear egress complexMayuri Sharma, Brian J Bender, Jeremy P Kamil, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 8, 2015
Structure of a herpesvirus nuclear egress complex subunit reveals an interaction groove that is essential for viral replicationKendra E Leigh, Mayuri Sharma, My Sam Mansueto, et al.
Journal of Virology|February 22, 2013
Inactivation of retinoblastoma protein does not overcome the requirement for human cytomegalovirus UL97 in lamina disruption and nuclear egressNatalia I Reim, Jeremy P Kamil, Depeng Wang, et al.
The Journal of Infectious Diseases|December 3, 2022
Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement SystemEduardo J M Nascimento, Brooke Norwood, Eloi Kpamegan, et al.
Vaccine|February 21, 2026
Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trialSanja Mandaric, Heather Friberg, Raphael Gottardo, et al.
NPJ Vaccines|May 25, 2023
Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adultsInge LeFevre, Lulu Bravo, Nicolas Folschweiller, et al.
The Journal of Infectious Diseases|June 30, 2022
Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue VaccineChristina R DeMaso, Lovkesh Karwal, Melissa Zahralban-Steele, et al.
NPJ Vaccines|October 17, 2024
Long term T cell response and safety of a tetravalent dengue vaccine in healthy childrenSanja Mandaric, Heather Friberg, Xavier Saez-Llorens, et al.
Pageof 4